Health Care • Biotechnology: Pharmaceutical Preparations
$10.36 ▲ +0.05
(+0.49%)
MKT CAP: $615.2M • VOL: 507.9K
52W L $8 52W H $15
ROARABLE / RQD
D- • 40/100
PIOTROSKI
4 / 9
ZVRA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$62.9M | -$87.0M | -$49.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $83.2M | -$105.5M | -$46.0M |
| EBITDA (Normalized) | -$62.3M | -$87.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$1.6M | -$69.7M | -$33.5M |
| Capital Expenditures (CapEx) | $835.0K | $0 | — |
| Free Cash Flow (FCF) | -$2.4M | -$69.7M | -$33.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -32.3% | -45.0% | — |
| Cash & Short-Term Equivalents | $62.4M | $33.8M | — |
| Total Debt (Short + Long Term) | $61.9M | $59.5M | — |
| Total Stockholders' Equity | $154.7M | $39.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZVRA.